<DOC>
	<DOCNO>NCT00073957</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan rituximab , locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Combining yttrium Y 90 ibritumomab tiuxetan rituximab may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine yttrium Y 90 Ibritumomab tiuxetan rituximab treat patient relapsed refractory diffuse large B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan Rituximab Treating Patients With Relapsed Refractory Diffuse Large B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine best overall response patient relapse refractory diffuse large B-cell non-Hodgkin 's lymphoma treat yttrium Y 90 ibritumomab tiuxetan rituximab . - Determine event-free survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This open-label , multicenter study . - Radioimmunotherapy : Patients receive indium In 111 ibritumomab tiuxetan IV 10 minute day 1 ( image ) ; yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 8 ; rituximab IV 3-4 hour day 1 , 8 , 15 , 22 , 29 , 36 . - CNS prophylaxis : Patients receive CNS prophylaxis comprise intrathecal ( IT ) methotrexate IT cytarabine day 15 , 22 , 29 , 36 OR IT cytarabine ( liposomal ) day 15 29 . - Maintenance rituximab : Patients assess response week 14 . Beginning month 6 , patient stable respond disease receive maintenance therapy comprise rituximab IV 3-4 hour weekly 4 week . Maintenance therapy repeat every 6 month 2 year ( total 4 course ) absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell nonHodgkin 's lymphoma , include follow : Bcell diffuse large cell variant Immunoblastic Mediastinal ( thymic ) large cell Tcell/histiocyterich Anaplastic large Bcell Intravascular large Bcell Lymphomatoid granulomatosis Relapsed refractory disease least 1 prior chemotherapy regimen require treatment Relapsed disease , define follow : Appearance new lesion OR increase least 50 % size previously involve site 50 % increase great diameter previously identify node great 1 cm short axis OR sum perpendicular diameter ( SPD ) 1 node Progressive disease , define follow : 50 % increase nadir SPD previously identify abnormal node Appearance new lesion end therapy CD20positive disease immunohistochemistry Bidimensionally measurable disease At least 1 lesion least 2.0 cm CT scan Less 25 % bone marrow involvement lymphoma No transform lymphoma indolent aggressive No HIV AIDSrelated lymphoma No hypocellular bone marrow No mark reduction bone marrow precursor 1 cell line ( e.g. , granulocytic , megakaryocytic , erythroid ) No CNS lymphoma Ineligible myeloablative therapy OR refuse transplantation Ineligible open yttrium Y 90 ibritumomab tiuxetan investigational protocol PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Lymphocyte count great 5,000/mm^3 ( patient small lymphocytic lymphoma ) Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL Renal Creatinine great 2.0 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study participation No concurrent serious nonmalignant disease infection would preclude study participation No human antimurine antibody reactivity PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior autologous bone marrow transplantation No prior peripheral blood stem cell rescue No prior fail stem cell collection Prior rituximab within past 90 day allow provided patient fludeoxyglucoseavid disease also indium In 111 ibritumomab tiuxetanavid disease least 1 lesion More 2 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy No prior radioimmunotherapy No prior external beam radiotherapy ( involved field regional ) 25 % active bone marrow Surgery More 4 week since prior major surgery ( except diagnostic surgery ) Other Recovered prior therapy More 4 week since prior therapy lymphoma More 8 week since prior phase II investigational drug No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>